1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > ImmuVen, Inc. - Product Pipeline Review - 2014

ImmuVen, Inc. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 20 pages

ImmuVen, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘ImmuVen, Inc. - Product Pipeline Review - 2014’, provides an overview of the ImmuVen, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmuVen, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ImmuVen, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ImmuVen, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ImmuVen, Inc.’s pipeline products

Reasons to buy

- Evaluate ImmuVen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ImmuVen, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ImmuVen, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ImmuVen, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmuVen, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ImmuVen, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

ImmuVen, Inc. - Product Pipeline Review - 2014
Table of Contents

ImmuVen, Inc. Snapshot 4
ImmuVen, Inc. Overview 4
Key Information 4
Key Facts 4
ImmuVen, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
ImmuVen, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
ImmuVen, Inc. - Pipeline Products Glance 9
ImmuVen, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
ImmuVen, Inc. - Drug Profiles 11
IMV-01 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
IMV-0123 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
IMV-02 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
IMV-03 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
ImmuVen, Inc. - Pipeline Analysis 15
ImmuVen, Inc. - Pipeline Products by Target 15
ImmuVen, Inc. - Pipeline Products by Molecule Type 16
ImmuVen, Inc. - Pipeline Products by Mechanism of Action 17
ImmuVen, Inc. - Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables

ImmuVen, Inc., Key Information 4
ImmuVen, Inc., Key Facts 4
ImmuVen, Inc. - Pipeline by Indication, 2014 6
ImmuVen, Inc. - Pipeline by Stage of Development, 2014 7
ImmuVen, Inc. - Monotherapy Products in Pipeline, 2014 8
ImmuVen, Inc. - Preclinical, 2014 9
ImmuVen, Inc. - Discovery, 2014 10
ImmuVen, Inc. - Pipeline by Target, 2014 15
ImmuVen, Inc. - Pipeline by Molecule Type, 2014 16
ImmuVen, Inc. - Pipeline Products by Mechanism of Action, 2014 17

List of Figures

ImmuVen, Inc. - Pipeline by Top 10 Indication, 2014 6
ImmuVen, Inc. - Pipeline by Stage of Development, 2014 7
ImmuVen, Inc. - Monotherapy Products in Pipeline, 2014 8
ImmuVen, Inc. - Pipeline by Top 10 Target, 2014 15
ImmuVen, Inc. - Pipeline by Top 10 Molecule Type, 2014 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.